Survodutide Phase 3 Trial Investigates Weight Loss in Non-Diabetic Adults

Obesity and overweight are global health crises, significantly increasing the risk of numerous chronic conditions like cardiovascular disease, type 2 diabetes, and certain cancers. While existing weight-loss medications have shown efficacy, there remains a critical need for novel, highly effective treatments, particularly for individuals without type 2 diabetes who often face unique metabolic challenges. This study specifically addresses the knowledge gap regarding the efficacy and safety of survodutide as a once-weekly treatment for weight management in adults living with overweight or obesity who do not have diabetes.

As a recently completed Phase 3 trial (completion expected February 2026), the specific efficacy and safety results for survodutide are not yet publicly available. However, the study was designed to rigorously evaluate the primary outcome of significant body weight reduction compared to placebo in non-diabetic adults. The primary objective is to determine the percentage change in body weight from baseline to week 76 in participants treated with survodutide compared to placebo. Secondary endpoints are expected to include the proportion of participants achieving at least 5%, 10%, and 15% body weight reduction, as well as changes in various cardiometabolic parameters. The trial's robust design with 726 participants over 76 weeks aims to provide definitive evidence on survodutide's potential as a leading weight-loss therapy.